{"id":"CU23253","slug":"bispecific-molecule-for-potent--CU23253","source":{"id":"CU23253","dataset":"techtransfer","title":"Bispecific molecule for potent HIV latency reversal","description_":"<p>This technology is a method to target and eliminate the viral reservoir of latent HIV-1 using latency reversal agents facilitated by targeted delivery with bispecific monoclonal antibodies.</p>\r\r<h2>Unmet Need: Method for efficient, specific delivery of HIV-1 latency reversal agents</h2>\r\r<p>Current techniques to treat HIV involve the use of antiretroviral therapies to reduce HIV levels in the blood to undetectable levels. However, these therapies are unable to eliminate latent viral reservoir, which is established during primary HIV infection and comprised of subpopulations of CD4+ resting memory T cells. Latency reversal agents have been developed to target and eliminate the latent reservoir by inducing HIV-1 expression in infected cells. Existing latency reversal agents tested in clinical trials do not efficaciously reduce latent viral reservoirs to concentrations deemed therapeutically relevant. Concerns over the safety profile of existing latency reversal agents further limit their potential and restricts their potential application to very low doses.</p>\r\r<h2>The Technology: Targeted delivery of a potent HIV latency reversal agent</h2>\r\r<p>This technology is a bispecific antibody-like molecule that enables targeted delivery of a potent HIV latency reversal agent. This molecule targets both CD4+ T-cells and the IL-15 receptor, increasing the effectiveness and specificity of the approach. The technology may be used to selectively reverse HIV latency in CD4+ T cell populations with refined accuracy as compared to existing latency reversal agents. This technology can serve as a treatment for HIV and a safe and efficacious method to perturb the HIV-1 latency reservoir in research and clinical settings.</p>\r\r<p>This technology has been validated <i>in vitro</i> using samples from HIV-1 patients.</p>\r\r<h2>Applications:</h2>\r\r<ul>\r<li>Treatment for HIV</li>\r<li>Research model for studying HIV-1 latency reservoir</li>\r<li>Research and molecular platform to target CD4+ T cells</li>\r<li>Combination therapy with pre- and post-exposure prophylaxis </li>\r<li>Targeted delivery of current latency reversal agents</li>\r<li>Combination therapy for HIV</li>\r</ul>\r\r<h2>Advantages:</h2>\r\r<ul>\r<li>Specifically targets the latent HIV-1 reservoir in lymphocytes</li>\r<li>Enables targeted delivery with increased specificity to CD4+ T cells</li>\r<li>Induces HIV latency reservoir reactivation <i>in vitro</i></li>\r<li>Compatible with the use of other latency reversal agents for synergy and improved efficacy</li>\r<li>Can be used in combination with antiretroviral therapies</li>\r<li>Increases treatment effectiveness via conjugation to other inhibitors</li>\r</ul>\r\r<h2>Lead Inventor:</h2>\r\r<p><a href=\"https://microbiology.columbia.edu/faculty-david-ho\">David Ho, M.D.</a></p>\r\r<h2>Patent Information:</h2>\r\r<p>Patent Pending(US<a href=\"https://globaldossier.uspto.gov/details/US/19327506/A/122971\">20260139037</a>)</p>\r\r<h2>Tech Ventures Reference:</h2>\r\r<ul>\r<li><p>IR CU23253</p></li>\r<li><p>Licensing Contact: <a href=\"mailto:techtransfer@columbia.edu\">Kristin Neuman</a> </p></li>\r</ul>\r","tags":["Antiviral drug","CD4","Combination therapy","Lymphocyte","Memory","Molecule","T cell","T helper cell","Virus latency"],"file_number":"CU23253","collections":[{"key":604,"name":"Immunology & Inflammation"}],"meta_description":"Bispecific antibody targets CD4+ T cells and IL-15 receptor to deliver latency reversal agents, aiming precise HIV latency disruption.","apriori_judge_output":"{\"scores\":{\"novelty\":4.0,\"potential_impact\":4.0,\"readiness\":2.0,\"scalability\":3.0,\"timeliness\":3.0},\"weighted_score\":3.35,\"risks\":[\"Preclinical in vitro validation only; translational/in vivo efficacy and safety unknown\",\"Bispecific construct may face manufacturability and regulatory complexity\",\"Potential off-target IL-15 receptor engagement risks\",\"Limited clarity on in vivo pharmacokinetics and latency reversal durability\"],\"one_sentence_take\":\"Promising novel bispecific approach with solid novelty and potential impact, but readiness and translational risk require substantial validation and regulatory planning.\"}","inventors":["David Da-i Ho M.D.","Hiroshi Mohri","Jian Yu","Manoj S. Nair","Yaoxing Huang"],"manager":"Kristin Neuman","depts":["Aaron Diamond AIDS Research Center (ADARC)","Medicine"],"divs":["Columbia University Medical Center (CUMC)"],"date_released":"2024-10-25"},"highlight":{},"matched_queries":null,"score":0.0}